Rosacea - Pipeline Review, H1 2017

Published: May, 2017 | Pages: 58 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rosacea - Pipeline Review, H1 2017, provides an overview of the Rosacea (Dermatology) pipeline landscape.

Rosacea is a chronic and potentially life-disruptive disorder primarily of the facial skin, often characterized by flare-ups and remissions. Symptoms include frequent redness of the face, or flushing, small, red lines under the skin, a swollen nose and thick skin, usually on the forehead, chin, and cheeks. The predisposing factors include age and family history of rosacea. Treatment includes antibiotics and acne drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rosacea - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Rosacea (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rosacea (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Rosacea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 8, 5, 1 and 1 respectively.

Rosacea (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Rosacea (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Rosacea (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rosacea (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Rosacea (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Rosacea (Dermatology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Rosacea (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Rosacea (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Rosacea - Overview
Rosacea - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Rosacea - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Rosacea - Companies Involved in Therapeutics Development
Amorepacific Corp
BioPharmX Inc
Cutanea Life Sciences Inc
ELORAC Inc
Foamix Pharmaceuticals Ltd
Hovione FarmaCiencia SA
Promius Pharma LLC
Sol-Gel Technologies Ltd
Rosacea - Drug Profiles
AC-701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACUD-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
benzoyl peroxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
carbamide peroxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DFD-29 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DMT-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DMT-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DMT-220 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EP-0003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FMX-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
itraconazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
minocycline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
minocycline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MSB-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omiganan pentahydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PAC-14028 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rosacea - Dormant Projects
Rosacea - Discontinued Products
Rosacea - Product Development Milestones
Featured News & Press Releases
Jan 18, 2017: Dermata Therapeutics Announces Initiation of Treatment in a Phase 2 Acne Rosacea Clinical Study
Sep 28, 2016: Dermata Therapeutics, LLC Announces Positive Top-line Results from their Phase 1 Pharmacokinetic Study of DMT210 in Acne Rosacea Patients
Sep 12, 2016: Foamix Announces Positive Topline Results from Phase 2 Trial Evaluating FMX-103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea
Sep 09, 2016: Foamix to Announce Topline Results in Phase 2 Clinical Trial of FMX-103 Minocycline Topical Foam for Moderate-to-Severe Papulopustular Rosacea
May 19, 2016: Galderma Laboratories Announces Availability of New Mirvaso (brimonidine) Topical Gel, 0.33% Pump Dispenser for the Treatment of the Persistent Facial Redness of Rosacea
May 16, 2016: Dermata Therapeutics Announces Initiation of Phase 1 Pharmacokinetic Study
May 03, 2016: Foamix Announces Completion of Enrollment in Phase 2 Clinical Trial of Minocycline Foam (FMX103) for Treatment of Papulopustular Rosacea
Oct 20, 2015: Foamix Announces Enrollment of First Patient in Phase 2 Clinical Trial of FMX103 in Papulopustular Rosacea
Apr 17, 2014: Treatment for Facial Redness Associated With Rosacea Now Available in the UK
Feb 26, 2014: mirvaso the first and only treatment targeting the facial redness of rosacea approved by the european commission
Jan 29, 2014: Galderma Announces the Publication of Positive Results of the Long-Term Study of Mirvaso Gel for Treatment of Persistent Erythema of Rosacea
Dec 20, 2013: Galderma Receives CHMP Positive Opinion For Mirvaso
Sep 27, 2013: Galderma Announces Availability of Mirvaso (brimonidine) Topical Gel, 0.33%
Aug 26, 2013: Galderma Receives FDA Approval of Mirvaso
Jul 08, 2013: Signum Dermalogix Investigational New Drug Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Rosacea, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Rosacea - Pipeline by Amorepacific Corp, H1 2017
Rosacea - Pipeline by BioPharmX Inc, H1 2017
Rosacea - Pipeline by Cutanea Life Sciences Inc, H1 2017
Rosacea - Pipeline by ELORAC Inc, H1 2017
Rosacea - Pipeline by Foamix Pharmaceuticals Ltd, H1 2017
Rosacea - Pipeline by Hovione FarmaCiencia SA, H1 2017
Rosacea - Pipeline by Promius Pharma LLC, H1 2017
Rosacea - Pipeline by Sol-Gel Technologies Ltd, H1 2017
Rosacea - Dormant Projects, H1 2017
Rosacea - Discontinued Products, H1 2017